CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 116 enrolled
Drug / intervention
dRAST +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03611257
NCT03611257N/ACompleted

Effect of Direct Rapid Antibiotic Susceptibility Testing (dRAST) on Treatment for Bacteremia in Patients With Hematologic Diseases: Randomized Controlled Trial

Seoul National University Hospital·interventional·Posted Aug 2, 2018·Updated Oct 14, 2019

In Brief

A clinical study evaluating dRAST and Current standard method for Hematologic Diseases and Bacteremia Sepsis. Completed, enrolled 116 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (dRAST), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with hematologic disease who received appropriate antibiotics in early period of bacteremia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2, 2018
Enrollment StartSep 1, 2018
Primary CompletionSep 15, 2019
Study CompletionOct 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.9 years ago

Interventions

dRASTother

Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.

Current standard methodother

Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.